BRAF and central nervous system cancer: Trametinib has been evaluated in pediatric clinical trials for tumors with activation of the MAPK pathway and has been recently authorized, in combination with the BRAF inhibitor dabrafenib, for the management of childhood gliomas harboring BRAF V600E mutations.